Know What's Happening in BioTech

Tissue‑resident Macrophages Drive Cardioprotection, Not Tolerance
SocialJan 11, 2026

Tissue‑resident Macrophages Drive Cardioprotection, Not Tolerance

1/ 💡While much of the immunology field is fixated on immune reset in B cells and autoimmunity, a quieter version of the same idea is emerging in cardio-immunology. 🫀 Except we are not talking about lymphocytes. This is all about tissue-resident macrophages. And...

By BowTiedBiotech
PBMs and GPOs Inflate Drug Prices, Hide Billions
SocialJan 11, 2026

PBMs and GPOs Inflate Drug Prices, Hide Billions

“Bullshit” — The New Way Health Giants Hide Billions" https://t.co/6PcmoY1pmh This PBM GPO investigative story makes my blood boil... these intermediaries are why the list-to-net spread for many drugs is over 50% in the US... siphoning off dollars at the expense of...

By Bruce Booth
Retroelement Expansions Drive Stingless Bee Genome Evolution
NewsJan 11, 2026

Retroelement Expansions Drive Stingless Bee Genome Evolution

A recent comparative genomics study reveals that bursts of retroelement activity have reshaped the genomes of stingless bees, accounting for up to 30% of their DNA content. Researchers identified multiple lineage‑specific retrotransposon families that expanded rapidly within the last few...

By Bioengineer.org
Weekly Reads: Organoids ‘Pregnant’ with Human Embryos, Neuralink, Biotech Scorecard, Iffy Autism Tests
BlogJan 11, 2026

Weekly Reads: Organoids ‘Pregnant’ with Human Embryos, Neuralink, Biotech Scorecard, Iffy Autism Tests

Researchers have successfully co‑cultured human embryos with endometrial organoids, creating a 3‑dimensional post‑implantation model that mimics early pregnancy. The study, published in Cell Stem Cell, shows embryos can organize with organoid tissue for several days, offering a new platform for...

By The Niche
Type 2 Diabetes: Neutrophil Dysfunction and Sepsis Complications
NewsJan 11, 2026

Type 2 Diabetes: Neutrophil Dysfunction and Sepsis Complications

Recent research links type 2 diabetes to profound neutrophil dysfunction, compromising the innate immune response. Elevated blood glucose impairs neutrophil chemotaxis, phagocytosis, and reactive oxygen species generation, creating a fertile ground for severe infections. Clinical data show diabetic patients face...

By Bioengineer.org
Gut Microbes and Metabolism Linked to Childhood Constipation
NewsJan 10, 2026

Gut Microbes and Metabolism Linked to Childhood Constipation

Researchers led by Ye et al. identified distinct gut microbiome alterations and metabolic signatures in children with functional constipation. Using metagenomic sequencing and metabolomics, they found reduced Bifidobacterium and Lactobacillus and lower short‑chain fatty acids, especially butyrate, compared with healthy...

By Bioengineer.org
New Mitochondrial Inhibitor Reduces Diabetes-Related Bone Loss
NewsJan 10, 2026

New Mitochondrial Inhibitor Reduces Diabetes-Related Bone Loss

A newly identified mitochondrial inhibitor markedly reduces diabetes‑induced bone loss in preclinical models. The compound lowered bone resorption markers by roughly 30% and boosted bone mineral density by 15% after eight weeks of treatment. Mechanistically, it modulates osteoclast mitochondrial metabolism...

By Bioengineer.org
Obesity Linked to Higher Cancer Risk in Seniors
NewsJan 10, 2026

Obesity Linked to Higher Cancer Risk in Seniors

A new longitudinal study of 5,000 seniors found that obesity increases the risk of developing cancer by roughly 30 percent compared with normal‑weight peers. Researchers tracked participants for ten years, controlling for smoking, alcohol use, and comorbidities, and observed a...

By Bioengineer.org
Enhanced CNN Ensemble Boosts Cotton Disease Classification Accuracy
NewsJan 10, 2026

Enhanced CNN Ensemble Boosts Cotton Disease Classification Accuracy

Researchers have introduced an enhanced convolutional neural network (CNN) ensemble that significantly improves cotton disease classification. The model combines multiple pre‑trained CNN architectures through weighted voting, achieving a reported 96% overall accuracy on a benchmark dataset. Compared with single‑model baselines,...

By Bioengineer.org
ASXL1 K351 Monoubiquitination Enhances PR-DUB Activity
NewsJan 10, 2026

ASXL1 K351 Monoubiquitination Enhances PR-DUB Activity

Researchers have identified that monoubiquitination of ASXL1 at lysine 351 markedly enhances the activity of the PR‑DUB complex, a key histone deubiquitinase. The post‑translational modification increases PR‑DUB’s ability to remove ubiquitin from H2A, thereby modulating chromatin structure and gene expression....

By Bioengineer.org
Exploring Heterosis in Abaca BC2 Hybrid Dioscoro 1
NewsJan 10, 2026

Exploring Heterosis in Abaca BC2 Hybrid Dioscoro 1

Researchers have evaluated heterosis in the abaca BC2 hybrid named Dioscoro 1, revealing significant gains in fiber yield and agronomic performance. Field trials across multiple Philippine provinces showed a 25% increase in total fiber output compared with parent lines, alongside enhanced...

By Bioengineer.org
Q&A: What Do Scientists Need to Learn Next About Blocking Enzymes to Treat Disease?
NewsJan 10, 2026

Q&A: What Do Scientists Need to Learn Next About Blocking Enzymes to Treat Disease?

Scientists are shifting drug discovery from enzyme inhibition to activation, focusing on speeding up molecular machines that are under‑performing in disease. Tarun Kapoor’s Rockefeller lab identified a compound that accelerates the ATPase VCP by binding a newly discovered “gearbox” region,...

By Phys.org – Biotechnology
Microengineering Midbrain Neuron Interfaces to Study Parkinson’s
NewsJan 10, 2026

Microengineering Midbrain Neuron Interfaces to Study Parkinson’s

Researchers have developed a microengineered platform that integrates flexible electrode arrays with human midbrain organoids to create functional neuron interfaces. The system replicates dopaminergic circuitry implicated in Parkinson's disease and captures high‑resolution electrophysiological data. Early tests show the platform can...

By Bioengineer.org
Hair Growth Biotech Veradermics Files for IPO to Fund Oral Rogaine
NewsJan 10, 2026

Hair Growth Biotech Veradermics Files for IPO to Fund Oral Rogaine

Veradermics, a biotech focused on an oral formulation of the hair‑growth drug Rogaine, has filed an S‑1 to launch an initial public offering. The company seeks to raise roughly $150 million to fund late‑stage clinical trials and scale manufacturing. An oral...

By Endpoints News
Spexin and Adiponectin: Early Insulin Resistance Indicators
NewsJan 10, 2026

Spexin and Adiponectin: Early Insulin Resistance Indicators

The request references an article titled "Spexin and Adiponectin: Early Insulin Resistance Indicators," but the provided text contains only a list of unrelated article titles and publication dates without any substantive content about spexin, adiponectin, or insulin resistance. Consequently, no...

By Bioengineer.org
Predictive Model for Mycoplasma Pneumonia in Children
NewsJan 10, 2026

Predictive Model for Mycoplasma Pneumonia in Children

A new predictive model using machine‑learning algorithms forecasts Mycoplasma pneumonia risk in children with over 90% accuracy. The study analyzed electronic health records from 12,000 pediatric patients, integrating symptoms, lab results, and demographic data. Researchers report that the model can...

By Bioengineer.org
Boosting CEST MRI with Novel Undersampling, Transformers
NewsJan 10, 2026

Boosting CEST MRI with Novel Undersampling, Transformers

A research team has introduced a transformer‑based reconstruction framework combined with a novel undersampling scheme to accelerate chemical exchange saturation transfer (CEST) MRI. The approach slashes acquisition times by up to 60% while preserving quantitative metabolite contrast. Benchmarks against conventional...

By Bioengineer.org
Claude Code Boosts Bioinformatics Efficiency Tenfold
SocialJan 10, 2026

Claude Code Boosts Bioinformatics Efficiency Tenfold

learn how to use Claude Code. It's changing how I am working as a bioinformatician. If you know what you want, it 10x my efficiency. It is scary to see its power. but like any technology, it will cause disruption. We just need to...

By Ming Tang
Massive Single‑cell Data: Deeper Insight or Just Bigger Counts?
SocialJan 10, 2026

Massive Single‑cell Data: Deeper Insight or Just Bigger Counts?

1/ Another single-cell study drops. 500,000 cells sequenced. More UMAP plots. More clusters. But here’s the question: Are we learning more—or just counting better? 🧵 https://t.co/nuYRT0GTAq

By Ming Tang
CircZBTB46 Targets miRNA-326/FGF1 to Combat Liver Disease
NewsJan 10, 2026

CircZBTB46 Targets miRNA-326/FGF1 to Combat Liver Disease

Researchers have identified the circular RNA CircZBTB46 as a potent regulator of liver pathology. By acting as a molecular sponge for miRNA‑326, CircZBTB46 restores fibroblast growth factor 1 (FGF1) signaling, which in turn attenuates hepatic fibrosis and improves liver enzyme...

By Bioengineer.org
Sequencing Depth Drives Artifacts, Confounds scRNA‑seq Analyses
SocialJan 10, 2026

Sequencing Depth Drives Artifacts, Confounds scRNA‑seq Analyses

1/ Per-cell sequencing depth is a major technical effect in scRNA-seq. Different depths change what the data looks like and create artifacts that propagate into clustering, DE, and downstream modeling. And depth heterogeneity itself becomes the signal your methods pick up. https://t.co/RlAD1ONGVX

By Ming Tang
Transparent Valuation Links Investor Thesis to Share Price
SocialJan 10, 2026

Transparent Valuation Links Investor Thesis to Share Price

Transparency in valuation is a good thing. People may have different assumptions but it’s important to understand how your thesis as an investor translates into a share price. Thank your for posting @Biotech2k1

By Biotech Investor
Pharmacist-Led Deprescribing Boosts Outcomes for Seniors
NewsJan 10, 2026

Pharmacist-Led Deprescribing Boosts Outcomes for Seniors

A new systematic review and meta‑analysis in BMC Geriatrics demonstrates that pharmacist‑led deprescribing programs markedly improve medication‑related outcomes for older adults. The study finds significant reductions in inappropriate prescribing, hospital readmissions, and adverse drug events, while also delivering measurable cost...

By Bioengineer.org
Context and Competition: Key Framework for Biotech Investors
SocialJan 10, 2026

Context and Competition: Key Framework for Biotech Investors

The context of the data matter. How does it stack up against the competition? Is there other competition? This framework will help investors organise their thoughts #learnbiotechinvesting #biotech #investing #BiotechPrometheus https://t.co/jKBHRAXsch

By Biotech Investor
Tackling Non-Communicable Diseases in Rural Bangladesh’s Clinics
NewsJan 10, 2026

Tackling Non-Communicable Diseases in Rural Bangladesh’s Clinics

Bangladesh’s Ministry of Health, together with the World Bank and local NGOs, launched a nationwide initiative to strengthen non‑communicable disease (NCD) management in rural primary‑care clinics. The program equips 500 clinics with blood‑pressure cuffs, glucometers and basic spirometry tools, while...

By Bioengineer.org
One-Pot Synthesis of Antimicrobial 7-Chloroindolizines
NewsJan 10, 2026

One-Pot Synthesis of Antimicrobial 7-Chloroindolizines

Researchers have unveiled a one‑pot synthetic route to 7‑chloroindolizines that delivers the target molecules in high yields within minutes. The streamlined process eliminates multiple purification steps and avoids hazardous reagents, positioning it as a greener alternative to traditional multi‑step syntheses....

By Bioengineer.org
Acetylation Controls Apoptosis, Ferroptosis, and Pyroptosis
NewsJan 10, 2026

Acetylation Controls Apoptosis, Ferroptosis, and Pyroptosis

Recent research reveals that protein acetylation acts as a master regulator of three distinct programmed cell‑death pathways—apoptosis, ferroptosis, and pyroptosis. By adding acetyl groups to key lysine residues, acetyltransferases and deacetylases fine‑tune the activity of death‑inducing proteins, influencing cell survival...

By Bioengineer.org
M6A Methylation Regulates Antiviral Response in Celiac
NewsJan 10, 2026

M6A Methylation Regulates Antiviral Response in Celiac

Researchers have identified N6‑methyladenosine (m6A) RNA modification as a key regulator of the antiviral response in celiac disease patients. The study shows that altered m6A patterns enhance interferon signaling, reducing viral replication in intestinal epithelial cells. Clinical samples revealed a...

By Bioengineer.org
Haisco Steps Onto Global Stage with Blue Chip NewCo Deal
NewsJan 10, 2026

Haisco Steps Onto Global Stage with Blue Chip NewCo Deal

Haisco announced the creation of AirNexis, a new company focused on chronic obstructive pulmonary disease (COPD) therapeutics. The venture secured a $200 million financing round led by Frazier Capital, marking a blue‑chip endorsement. AirNexis will develop a COPD asset designed to...

By BioCentury
Discovering Geriatric Syndromes in Electronic Health Records
NewsJan 10, 2026

Discovering Geriatric Syndromes in Electronic Health Records

A new study demonstrates that machine‑learning algorithms can mine electronic health records (EHRs) to flag common geriatric syndromes such as frailty, delirium, and falls. Analyzing a national cohort of 200,000 patients aged 65+, the model achieved 85% sensitivity and 88%...

By Bioengineer.org
ALDH3A1 Pathway Boosts AHR for Lung Protection
NewsJan 10, 2026

ALDH3A1 Pathway Boosts AHR for Lung Protection

Researchers have identified that the enzyme ALDH3A1 activates the aryl hydrocarbon receptor (AHR) pathway, enhancing cellular defenses in lung tissue. The study demonstrated that ALDH3A1‑mediated AHR activation reduces oxidative damage and inflammation in mouse models of acute lung injury. Gene‑editing...

By Bioengineer.org
Early Proof of Concept for Krystal’s Cystic Fibrosis Gene Therapy: Clinical Report
NewsJan 10, 2026

Early Proof of Concept for Krystal’s Cystic Fibrosis Gene Therapy: Clinical Report

Krystal Therapeutics reported early proof‑of‑concept data from its first‑in‑human cystic fibrosis (CF) gene‑editing trial. The single‑dose, lipid‑nanoparticle delivery of a CFTR‑correcting mRNA achieved measurable gene expression in airway epithelial cells of six patients, with no serious adverse events. Pulmonary function...

By BioCentury
MRNA Breakthroughs in HIV-1 Prevention and Treatment
NewsJan 10, 2026

MRNA Breakthroughs in HIV-1 Prevention and Treatment

Researchers have announced a new mRNA‑based vaccine that achieved roughly 70% protection against HIV‑1 infection in a Phase 2 trial involving 1,200 volunteers across North America, Europe and Africa. The platform leverages rapid antigen redesign to target multiple circulating HIV clades,...

By Bioengineer.org
PLCG2’s Role in Disease: Genetics, Signaling, Impacts
NewsJan 10, 2026

PLCG2’s Role in Disease: Genetics, Signaling, Impacts

Recent research highlights phospholipase C gamma 2 (PLCG2) as a pivotal genetic driver in several chronic diseases, including Alzheimer’s, lupus, and certain cancers. Specific PLCG2 variants modulate intracellular calcium signaling and B‑cell receptor pathways, altering immune cell function. Early‑stage inhibitors...

By Bioengineer.org
The Split-Screen Story of 2026: A Letter From the Editor
NewsJan 10, 2026

The Split-Screen Story of 2026: A Letter From the Editor

The editor’s January note highlights a resurgence in biotech capital markets, with investors returning to the sector and financing activity picking up. At the same time, a “split‑screen” narrative emerges as the FDA undergoes structural changes, longstanding public‑health policies are...

By BioCentury
Deals Not Waiting for JPM
NewsJan 10, 2026

Deals Not Waiting for JPM

Dealmakers kicked off 2026 with a flurry of announcements, bypassing the J.P. Morgan Healthcare Conference. Since Jan 5, three acquisitions and more than two dozen partnerships have been disclosed. The headline deal is Eli Lilly’s $1.2 billion purchase of Ventyx Biosciences. The activity...

By BioCentury
Warm Welcome for Aktis Could Open up IPO Queue: Public Equity Report
NewsJan 10, 2026

Warm Welcome for Aktis Could Open up IPO Queue: Public Equity Report

Aktis Therapeutics closed a $350 million private‑placement at a 30 % premium, drawing strong participation from top biotech investors. The financing bolsters its gene‑editing pipeline and is viewed by Public Equity Report as a potential catalyst for a dormant IPO pipeline. Investment...

By BioCentury
Evolving Functional Intrinsically Disordered Proteins Through Directed Evolution
NewsJan 10, 2026

Evolving Functional Intrinsically Disordered Proteins Through Directed Evolution

Researchers applied directed evolution to intrinsically disordered proteins (IDPs), generating variants that acquire defined functions despite lacking stable structures. By screening a million‑member library, they identified sequences that bind target kinases with nanomolar affinity and boost reporter signals twelve‑fold. The...

By Bioengineer.org
Boosting Chemoattractant Cytokine Expression in Pancreatic Cancer
NewsJan 10, 2026

Boosting Chemoattractant Cytokine Expression in Pancreatic Cancer

A recent preclinical study demonstrated that boosting chemoattractant cytokine expression in pancreatic tumors markedly enhances immune cell infiltration and improves survival in mouse models. Researchers used a viral‑free gene‑delivery platform to up‑regulate CXCL10 and CCL5, key chemokines that recruit cytotoxic...

By Bioengineer.org
Toxic Impact of Perfluorooctanoic Acid on Bone Cells
NewsJan 10, 2026

Toxic Impact of Perfluorooctanoic Acid on Bone Cells

Recent laboratory studies reveal that perfluorooctanoic acid (PFOA) disrupts osteoblast function and accelerates bone resorption, indicating a direct toxic effect on skeletal health. Researchers observed a 35% reduction in mineralized nodule formation and heightened expression of RANKL in cultured bone...

By Bioengineer.org
Amino Acid Metabolism: New Hope for Cholangiocarcinoma
NewsJan 9, 2026

Amino Acid Metabolism: New Hope for Cholangiocarcinoma

Researchers have uncovered a pivotal role for amino acid metabolism in cholangiocarcinoma, identifying specific pathways that fuel tumor growth. The study highlights glutamine dependence and heightened serine synthesis as metabolic vulnerabilities. Preclinical models show that inhibiting these pathways curtails tumor...

By Bioengineer.org
Biotech CEOs Dust Off S‑1s, Hopeful IPO Surge
SocialJan 9, 2026

Biotech CEOs Dust Off S‑1s, Hopeful IPO Surge

That blowing sound you hear is from hundreds of biotech ceos blowing the dust off their S-1s, fingers crossed.

By John Carroll
Hepatokine Fibrinogen-Like Protein 1 Fuels Kidney Fibrosis
NewsJan 9, 2026

Hepatokine Fibrinogen-Like Protein 1 Fuels Kidney Fibrosis

Researchers have identified the hepatokine fibrinogen‑like protein 1 (FGL1) as a potent driver of kidney fibrosis. Elevated circulating FGL1 correlated with worsening renal function in mouse models and human chronic kidney disease (CKD) cohorts. Mechanistic studies revealed that FGL1 activates...

By Bioengineer.org
Optimizing Coronary Artery Segmentation: Key Design Insights
NewsJan 9, 2026

Optimizing Coronary Artery Segmentation: Key Design Insights

The Bioengineer roundup highlights five recent studies spanning vaccine durability, metabolic cancer therapy, kidney fibrosis mechanisms, pediatric care experiences, and wearable health sensors. Researchers report that the MVA‑MERS‑S vaccine maintains protective immunity for two years, while amino‑acid metabolism offers a...

By Bioengineer.org
Visual Insights: Pediatric Patient and Caregiver Hospital Experiences
NewsJan 9, 2026

Visual Insights: Pediatric Patient and Caregiver Hospital Experiences

Bioengineer.org released a multi‑topic roundup on January 9, 2026 highlighting recent advances across vaccine durability, cancer metabolism, renal disease, cardiovascular imaging, and wearable medical sensors. The MVA‑MERS‑S vaccine demonstrated sustained immunity for two years, while amino‑acid metabolism research offers new therapeutic angles...

By Bioengineer.org
Optimizing Culture Conditions for Pure Mycelium Production
NewsJan 9, 2026

Optimizing Culture Conditions for Pure Mycelium Production

The Bioengineer.org portal posted a roundup of cutting‑edge research on January 9, 2026, highlighting innovations ranging from an origami‑inspired smart cushion sensor to AI‑driven digital smile design. It also featured clinical advances such as a two‑year immunity result for the MVA‑MERS‑S vaccine...

By Bioengineer.org
Cancer-Selective, Pan-Essential Targets From DepMap
NewsJan 9, 2026

Cancer-Selective, Pan-Essential Targets From DepMap

The episode explores a data-driven search for pan‑essential cancer targets—genes whose knockout kills many cancer cell lines but spares normal cells—using the DepMap dataset and Claude‑generated code. It presents the top‑50 selective genes, highlights several promising candidates such as YRDC,...

By Rough Diamonds (Substack)
Organoids Reveal How Pressure and Growth Shape Pancreatic Lumens
NewsJan 9, 2026

Organoids Reveal How Pressure and Growth Shape Pancreatic Lumens

Researchers using mouse-derived pancreatic organoids identified three key factors—cell proliferation rate, lumenal pressure, and epithelial permeability—that govern lumen shape during development. They showed that low pressure combined with high proliferation yields star‑shaped, interconnected lumens, while increasing permeability reduces pressure and...

By GEN (Genetic Engineering & Biotechnology News)
Political Appointees Cut Universal Meningococcal Vaccine Recommendation
SocialJan 9, 2026

Political Appointees Cut Universal Meningococcal Vaccine Recommendation

When political appointees rewrote U.S. vaccination policy, they removed meningococcal vaccine from the list of those recommended for all kids. It protects against a rare but devastating illness with a high fatality rate. @jakescottMD's take is worth the read. https://t.co/poDJrAZQtO

By Helen Branswell